文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

黏多糖贮积症中的视网膜病变

Retinopathy in Mucopolysaccharidoses.
PubMed 文献 · Ophthalmology · 2024-11-14

这项前瞻性纵向观察研究在2015年11月至2023年3月从曼彻斯特皇家眼科医院招募75例黏多糖贮积症(MPS)患者,通过眼底检查、超广角彩色眼底照相、眼底自发荧光、OCT和视网膜电图评估视网膜病变。32例确认存在视网膜病变,包括25例MPS I、4例MPS II、1例MPS IVA和2例MPS VI,最早在2岁即可检出。

要点

  • 75例MPS患者中32例确认视网膜病变,以MPS I最多(25例)。
  • 视网膜病变最早在2岁即可检出,初始检出年龄范围为2至53岁。
  • 32例中15例报告夜盲症状,21例视网膜电图异常。

核心结论

  • MPS患者最早在2岁即可通过眼底检查、眼科影像或视网膜电图诊断视网膜病变。
  • 新兴治疗包括基因治疗可能预防或稳定视网膜病变,因此MPS相关视网膜病变的表型数据和自然病史至关重要。

研究设计与样本

  • 前瞻性纵向观察研究,2015年11月至2023年3月从曼彻斯特皇家眼科医院眼科门诊招募MPS患者。
  • 共收集75例患者数据,包括45例MPS I、9例MPS II、13例MPS IVA和8例MPS VI,年龄3至53岁。
  • 65例接受眼底照相,61例接受眼底自发荧光,58例接受OCT,36例接受电生理检查。

主要发现

  • 32例确认视网膜病变,包括25例MPS I、4例MPS II、1例MPS IVA和2例MPS VI。
  • 5例通过临床检查首次诊断视网膜病变,31例通过超广角彩色眼底照相并辅以眼底自发荧光和OCT识别。
  • 21例显示与视网膜病变一致的视网膜电图异常,32例中15例报告夜盲症状。
  • 视网膜病变初始检出年龄为2至53岁,起病年龄差异很大。

关键数值与推荐

  • 视网膜病变定义为视网膜检查或眼底照相可见的视网膜疾病征象,如脱色素、骨细胞样色素沉着、血管迂曲、视网膜色素上皮斑驳或其他改变、黄斑萎缩/皱褶/视网膜前膜。
  • 眼底自发荧光表现包括中心高自发荧光点、黄斑旁高自发荧光环、黄斑周围低自发荧光病灶(双牛眼)、高/低自发荧光区域及黄斑外改变。
  • OCT特征包括中心外界膜增厚、视网膜色素上皮扰动、光感受器层丢失、黄斑旁视网膜萎缩及外层视网膜/脉络膜内空腔。
  • 视网膜电图显示视杆细胞介导的视网膜病变或视杆-视锥细胞营养不良。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the pattern(s) of onset, variation, and progression of retinopathy in patients with mucopolysaccharidoses (MPS). DESIGN: Prospective, longitudinal, observational study. PARTICIPANTS: Between November 2015 and March 2023, individuals with MPS were recruited from ophthalmology clinics at the Manchester Royal Eye Hospital, United Kingdom. METHODS: Participants underwent assessment of visual acuity, corneal clouding, and intraocular pressure, along with fundoscopy, ultrawidefield (UWF) color fundus photography, fundus autofluorescence (FAF) imaging, OCT, and electroretinography (ERG), where feasible. MAIN OUTCOME MEASURES: Evaluation of findings from clinical examination, retinal imaging, and ERG studies to ascertain the presence and patterns of retinopathy. RESULTS: Data were collected for 75 patients, including 45 with MPS I, 9 with MPS II, 13 with MPS IVA, and 8 with MPS VI, aged 3 to 53 years. Fundus photography was conducted in 65 patients, FAF in 61 patients, OCT in 58 patients, and electrodiagnostic studies in 36 patients. Retinopathy was defined as signs of retinal disease evident through retinal examination or fundus photography, such as depigmentation, bone-spicule pigmentation, vascular tortuosity, retinal pigment epithelium (RPE) mottling/other changes, macular atrophy/puckering/epiretinal membranes, FAF findings such as a central hyperautofluorescent dot, hyperautofluorescent parafoveal ring, hypoautofluorescent lesions around fovea (double bull's eye), areas of hyper/hypoautofluorescence, and extrafoveal changes, OCT imaging features such as central external limiting membrane (ELM) thickening, RPE disturbance, photoreceptor layer loss, parafoveal retinal atrophy, and outer retinal/intrachoroidal cavities, or ERG studies revealing rod-mediated retinopathy or rod-cone dystrophy. Retinopathy was confirmed in 32 patients, including 25 with MPS I, 4 with MPS II, 1 with MPS IVA, and 2 with MPS VI. Five participants were first diagnosed with retinopathy with clinical examination, and 31 participants were identified on UWF color fundus photography supported by FAF and OCT. A total of 21 patients exhibited ERG abnormalities consistent with retinopathy. Fifteen of the total 32 participants described symptoms of nyctalopia. The onset of retinopathy varied substantially, with initial detection between 2 and 53 years of age. CONCLUSIONS: Patients with MPS as young as 2 years may develop retinopathy, diagnosed through fundus examination, ophthalmic imaging, or ERG. Emerging treatments, including gene therapy, may prevent or stabilize retinopathy. Phenotypic data and natural history of MPS-related retinopathy are thus of paramount importance. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Noor M, Mehana O, Mata G, et al. Retinopathy in Mucopolysaccharidoses. Ophthalmology. 2024. PMID: 39547427. doi:10.1016/j.ophtha.2024.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。